Chronic Lymphocytic Leukemia and other Chronic Lymphoid Leukemias
- Lymphocyte immunophenotyping by flow cytometry can distinguish between malignant (clonal) and nonmalignant (nonclonal) causes of lymphocytosis and eliminates the need to rely on the duration or magnitude of the lymphocyte count elevation to differentiate CLL and other lymphoproliferative disorders from reactive causes of lymphocytosis.
- Chromosome analysis by FISH predicts patient survival. In a retrospective analysis of a heterogeneous patient population, many of whom had advanced-stage disease and were previously treated, Dohner and colleagues developed a hierarchical system that assigns patients to one of five categories with widely different median survival.
- The development and therapeutic application of anti-CD20 monoclonal antibodies in the 1990s revolutionized the care of patients with lymphoid malignancy. Several trials evaluated the efficacy of combining monoclonal antibodies with chemotherapy (CIT) for patients with CLL.